Carregant...
Tipus de document
ArticleVersió
Versió publicadaData de publicació
Llicència de publicació
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/193150
Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII)
Títol de la revista
Director/Tutor
ISSN de la revista
Títol del volum
Recurs relacionat
Resum
(1) Scant information is available concerning the characteristics that may favour the acquisition of COVID-19 in patients with inflammatory bowel disease (IBD). Therefore, the aim of this study was to assess these differences between infected and noninfected patients with IBD. (2) This nationwide case-control study evaluated patients with inflammatory bowel disease with COVID-19 (cases) and without COVID-19 (controls) during the period March-July 2020 included in the ENEIDA of GETECCU. (3) A total of 496 cases and 964 controls from 73 Spanish centres were included. No differences were found in the basal characteristics between cases and controls. Cases had higher comorbidity Charlson scores (24% vs. 19%; p = 0.02) and occupational risk (28% vs. 10.5%; p < 0.0001) more frequently than did controls. Lockdown was the only protective measure against COVID-19 (50% vs. 70%; p < 0.0001). No differences were found in the use of systemic steroids, immunosuppressants or biologics between cases and controls. Cases were more often treated with 5-aminosalicylates (42% vs. 34%; p = 0.003). Having a moderate Charlson score (OR: 2.7; 95%CI: 1.3-5.9), occupational risk (OR: 2.9; 95%CI: 1.8-4.4) and the use of 5-aminosalicylates (OR: 1.7; 95%CI: 1.2-2.5) were factors for COVID-19. The strict lockdown was the only protective factor (OR: 0.1; 95%CI: 0.09-0.2). (4) Comorbidities and occupational exposure are the most relevant factors for COVID-19 in patients with IBD. The risk of COVID-19 seems not to be increased by immunosuppressants or biologics, with a potential effect of 5-aminosalicylates, which should be investigated further and interpreted with caution.
Matèries (anglès)
Citació
Citació
ZABANA, Yamile, MARÍN JIMÉNEZ, Ignacio, RODRÍGUEZ LAGO, Iago, VERA, Isabel, MARTÍN ARRANZ, María dolores, GUERRA, Iván, GISBERT, Javier p., MESONERO, Francisco, BENÍTEZ, Olga, TAXONERA, Carlos, PONFERRADA DÍAZ, Ángel, PIQUERAS, Marta, LUCENDO, Alfredo j., CABALLOL, Berta, MAÑOSA, Míriam, MARTÍNEZ MONTIEL, Pilar, BOSCA WATTS, Maia, GORDILLO, Jordi, BUJANDA, Luis, MANCEÑIDO, Noemí, MARTÍNEZ PÉREZ, Teresa, LÓPEZ, Alicia, RODRÍGUEZ GUTIÉRREZ, Cristina, GARCÍA LÓPEZ, Santiago, VEGA, Pablo, RIVERO, Montserrat, MELCARNE, Luigi, CALVO, María, IBORRA, Marisa, BARREIRO DE ACOSTA, Manuel, SICILIA, Beatriz, BARRIO, Jesús, PÉREZ CALLE, José lázaro, BUSQUETS, David, PÉREZ MARTÍNEZ, Isabel, NAVARRO LLAVAT, Mercè, HERNÁNDEZ, Vicent, ARGÜELLES ARIAS, Federico, RAMÍREZ ESTESO, Fernando, MEIJIDE, Susana, RAMOS, Laura, GOMOLLÓN, Fernando, MUÑOZ, Fernando, SURIS, Gerard, ORTIZ DE ZARATE, Jone, HUGUET, José maría, LLAÓ, Jordina, GARCÍA SEPULCRE, Mariana fe, SIERRA, Mónica, DURÀ, Miguel, ESTRECHA, Sandra, FUENTES CORONEL, Ana, HINOJOSA, Esther, OLIVAN, Lorenzo, IGLESIAS, Eva, GUTIÉRREZ, Ana, VARELA, Pilar, RULL, Núria, GILABERT, Pau, HERNÁNDEZ CAMBA, Alejandro, BROTONS, Alicia, GINARD, Daniel, SESÉ, Eva, CARPIO, Daniel, ACEITUNO, Montserrat, CABRIADA, José luis, GONZÁLEZ LAMA, Yago, JIMÉNEZ, Laura, CHAPARRO, María, LÓPEZ SAN ROMÁN, Antonio, ALBA, Cristina, PLAZA SANTOS, Rocío, MENA, Raquel, TAMARIT SEBASTIÁN, Sonsoles, RICART, Elena, CALAFAT, Margalida, OLIVARES, Sonsoles, NAVARRO, Pablo, BERTOLETTI, Federico, ALONSO GALÁN, Horacio, PAJARES, Ramón, OLCINA, Pablo, MANZANO, Pamela, DOMÈNECH, Eugeni, ESTEVE, Maria, The ENEIDA Registry of GETECCU. Risk Factors for COVID-19 in Inflammatory Bowel Disease: A National, ENEIDA-Based Case–Control Study (COVID-19-EII). _Journal of Clinical Medicine_. 2022. Vol. 11, núm. 24, pàgs. 7540. [consulta: 22 de gener de 2026]. ISSN: 2077-0383. [Disponible a: https://hdl.handle.net/2445/193150]